Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients

NCT01970904 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

147

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C
Liver Disease

Interventions

DRUG: Alisporivir
DRUG: Ribavirin
DRUG: Peg-IFNα2a

Sponsor

Debiopharm International SA